Biocon gets approval for anti-CD-6 psoriasis biologic
This article was originally published in Scrip
As Biocon receives marketing authorization in India for its anti-CD6 monoclonal antibody, itolizumab, for chronic plaque psoriasis, analysts suggest that large markets like the US, EU and Japan hold significant promise for the product.
You may also be interested in...
Appellate board stays previous order that rescinded the patent on ceritinib in India, giving Novartis the upper hand for now. The spotlight is now on procedural aspects and additional evidence/submission by challenger Natco and rebuttal by the Swiss multinational.
Cipla’s generic of Merck & Co’s Proventil makes significant inroads in the US, with the Indian company confident that it has both a strong cost position and large capacity to take on competition. Pricing in the segment currently remains ‘respectable.’
White House directive aimed at reducing dependence on foreign manufacturers for essential medicines and a seemingly more aggressive stance towards site inspections could signal a worrying emerging trend for India pharma. But it also needs to be viewed through the prism of the upcoming US elections and trade tensions with China amid the pandemic.